Squadron Capital Management LLC — 13F Holdings & Portfolio
CIK 2050709 · latest 13F-HR filed 2026-08-14
Squadron Capital Management LLC manages $322.2M in 13F-reported U.S. long-equity assets across 43 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RLMD (15.78%), CCCC (10.43%), COGT (10.39%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions and exited 13; 10 existing positions rose in reported value and 4 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 73%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 18, 2013.
2 QUEEN'S ROAD CENTRAL
CENTRAL
Hong Kong
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CHIONG, JOYCE, MAY-WEI Control | CCO, CFO, DIRECTOR since Oct 2006 | Less than 5% | Individual |
| CHIU, JACOB, YEUNG BUN Control | DIRECTOR since Oct 2006 | Less than 5% | Individual |
| CHOW, ALICE, MING Control | DIRECTOR since Oct 2006 | Less than 5% | Individual |
| PIERCE, DAVID, GLEN Control | DIRECTOR since May 2006 | Less than 5% | Individual |
| SQUADRON CAPITAL MANAGEMENT LIMITED Control | SHAREHOLDER since May 2006 | 75% or more | Foreign Entity |
| 1999 LAWRENCE DESCENDANT'S TRUST Control Indirect owner via EDGEWATER INVESTMENT PARTNERS, L.P. | LIMITED PARTNER since Jan 2002 | 75% or more | Domestic Entity |
| EDGEWATER INVESTMENT PARTNERS, L.P. Control Indirect owner via FLAG CAPITAL MANAGEMENT, LLC | MEMBER since Jan 2002 | 25–50% | Domestic Entity |
| FLAG CAPITAL MANAGEMENT, LLC Control Indirect owner via SQUADRON CAPITAL MANAGEMENT LIMITED | SHAREHOLDER since Dec 2012 | 75% or more | Domestic Entity |
| FRAZIER, DIANA, HUMAN Control Indirect owner via STREAMLINER PARTNERS, L.P. | GENERAL PARTNER since Jan 2002 | General partner, trustee or manager | Individual |
| JOSH L. FRAZIER EXEMPTION TRUST UNDER THE DIANA H. FRAZIER 2000 DESCENDANTS TRUST Control Indirect owner via STREAMLINER PARTNERS, L.P. | LIMITED PARTNER since Jan 2002 | 75% or more | Domestic Entity |
| LAWRENCE, LOUIS, PETER Control Indirect owner via EDGEWATER INVESTMENT PARTNERS, L.P. | GENERAL PARTNER since Jan 2002 | General partner, trustee or manager | Individual |
| STREAMLINER PARTNERS, L.P. Control Indirect owner via FLAG CAPITAL MANAGEMENT, LLC | MEMBER since Jan 2002 | 25–50% | Domestic Entity |
Ownership & leadership changes · 1 filing with changes since Mar 29, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedSEARCH INVESTMENT OFFICE LIMITED · SHAREHOLDER · 75% or more · indirect via SQUADRON CAPITAL MANAGEMENT LIMITED · control person · listed since May 2006
- No longer listedTHE MICHARO TRUST · SHAREHOLDER · 75% or more · indirect via SEARCH INVESTMENT OFFICE LIMITED · control person · listed since Dec 2004
- No longer listedTHE MOUNTAIN TRUST COMPANY · TRUSTEE · General partner, trustee or manager · indirect via THE MICHARO TRUST · control person · listed since Dec 2004
- Added1999 LAWRENCE DESCENDANT'S TRUST · LIMITED PARTNER · 75% or more · indirect via EDGEWATER INVESTMENT PARTNERS, L.P. · control person
- AddedEDGEWATER INVESTMENT PARTNERS, L.P. · MEMBER · 25–50% · indirect via FLAG CAPITAL MANAGEMENT, LLC · control person
- AddedFLAG CAPITAL MANAGEMENT, LLC · SHAREHOLDER · 75% or more · indirect via SQUADRON CAPITAL MANAGEMENT LIMITED · control person
- AddedFRAZIER, DIANA, HUMAN · GENERAL PARTNER · General partner, trustee or manager · indirect via STREAMLINER PARTNERS, L.P. · control person
- AddedJOSH L. FRAZIER EXEMPTION TRUST UNDER THE DIANA H. FRAZIER 2000 DESCENDANTS TRUST · LIMITED PARTNER · 75% or more · indirect via STREAMLINER PARTNERS, L.P. · control person
- AddedLAWRENCE, LOUIS, PETER · GENERAL PARTNER · General partner, trustee or manager · indirect via EDGEWATER INVESTMENT PARTNERS, L.P. · control person
- AddedSTREAMLINER PARTNERS, L.P. · MEMBER · 25–50% · indirect via FLAG CAPITAL MANAGEMENT, LLC · control person
- ChangedPIERCE, DAVID, GLEN · title CEO & DIRECTOR → DIRECTOR
- ListedCHIONG, JOYCE, MAY-WEI · CCO, CFO, DIRECTOR · Less than 5% · control person
- ListedCHIU, JACOB, YEUNG BUN · DIRECTOR · Less than 5% · control person
- ListedCHOW, ALICE, MING · DIRECTOR · Less than 5% · control person
- ListedPIERCE, DAVID, GLEN · CEO & DIRECTOR · Less than 5% · control person
- ListedSEARCH INVESTMENT OFFICE LIMITED · SHAREHOLDER · 75% or more · indirect via SQUADRON CAPITAL MANAGEMENT LIMITED · control person
- ListedSQUADRON CAPITAL MANAGEMENT LIMITED · SHAREHOLDER · 75% or more · control person
- ListedTHE MICHARO TRUST · SHAREHOLDER · 75% or more · indirect via SEARCH INVESTMENT OFFICE LIMITED · control person
- ListedTHE MOUNTAIN TRUST COMPANY · TRUSTEE · General partner, trustee or manager · indirect via THE MICHARO TRUST · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- C4 THERAPEUTICS INC$27.7M +468.2%
- RELAY THERAPEUTICS INC$11.5M +171.2%
- ZENTALIS PHARMACEUTICALS INC$9.4M +111.2%
- INVENTIVA SA$6.2M +210.0%
- KODIAK SCIENCES INC$5.0M +34.5%
Top Trims
- RELMADA THERAPEUTICS INC-$8.1M -13.8%
- NEXTCURE INC-$2.7M -96.4%
- LIPOCINE INC NEW-$1.5M -42.3%
- PASITHEA THERAPEUTICS CORP-$1.0M -66.9%
New Positions
- ENLIVEN THERAPEUTICS INC$8.1M
- ADAGENE INC$5.2M
- FORTE BIOSCIENCES INC$4.8M
- INFLARX NV$4.5M
- ASSEMBLY BIOSCIENCES INC$4.4M
Exited Positions
- KALVISTA PHARMACEUTICALS INC$19.8M
- ABIVAX SA$14.5M
- NEKTAR THERAPEUTICS$9.0M
- SCYNEXIS INC$7.0M
- EUPRAXIA PHARMACEUTICALS INC$4.9M
Squadron Capital Management LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $50.9M | 15.78% | 7,350,000 | SH |
| 2 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $33.6M | 10.43% | 7,200,000 | SH |
| 3 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $33.5M | 10.39% | 865,000 | SH |
| 4 | KODIAK SCIENCES INC | KOD | 50015M109 | $19.5M | 6.05% | 500,000 | SH |
| 5 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $18.1M | 5.63% | 970,000 | SH |
| 6 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $17.9M | 5.57% | 3,700,000 | SH |
| 7 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $11.8M | 3.66% | 290,000 | SH |
| 8 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $10.0M | 3.10% | 335,000 | SH |
| 9 | INVENTIVA SA | IVA | 46124U107 | $9.2M | 2.86% | 2,435,000 | SH |
| 10 | ADLAI NORTYE LTD | ANL | 00704R109 | $8.8M | 2.73% | 764,876 | SH |
| 11 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $8.1M | 2.52% | 160,000 | SH |
| 12 | ARRIVENT BIOPHARMA INC Call | AVBP | 04272N102 | $6.4M | 1.97% | 183,000 | SH |
| 13 | PALISADE BIO INC | PALI | 696389402 | $6.3M | 1.95% | 3,000,000 | SH |
| 14 | BIOAGE LABS INC Call | BIOA | 09077V100 | $6.1M | 1.90% | 250,000 | SH |
| 15 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $6.1M | 1.89% | 3,000,000 | SH |
| 16 | ADAGENE INC | ADAG | 005329107 | $5.2M | 1.63% | 1,250,000 | SH |
| 17 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $4.8M | 1.48% | 225,000 | SH |
| 18 | REZOLUTE INC Call | RZLT | 76200L309 | $4.7M | 1.45% | 900,000 | SH |
| 19 | INFLARX NV | IFRX | N44821101 | $4.5M | 1.39% | 2,000,000 | SH |
| 20 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $4.4M | 1.36% | 160,000 | SH |
| 21 | COMPASS PATHWAYS PLC Call | CMPS | 20451W101 | $4.3M | 1.34% | 305,000 | SH |
| 22 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $4.3M | 1.33% | 324,977 | SH |
| 23 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $4.3M | 1.32% | 260,000 | SH |
| 24 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $4.2M | 1.32% | 300,000 | SH |
| 25 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $4.0M | 1.24% | 85,000 | SH |
| 26 | SOL-GEL TECHNOLOGIES LTD | SLGL | M8694L137 | $3.9M | 1.20% | 52,000 | SH |
| 27 | BIOAGE LABS INC | BIOA | 09077V100 | $3.8M | 1.18% | 155,000 | SH |
| 28 | SCYNEXIS INC | SCYX | 811292309 | $3.1M | 0.96% | 756,884 | SH |
| 29 | PROQR THRAPEUTICS N V | PRQR | N71542109 | $2.8M | 0.87% | 1,511,496 | SH |
| 30 | DISC MEDICINE INC Call | IRON | 254604101 | $2.2M | 0.68% | 30,000 | SH |
| 31 | REZOLUTE INC | RZLT | 76200L309 | $2.1M | 0.65% | 403,410 | SH |
| 32 | LIPOCINE INC NEW | LPCN | 53630X203 | $2.1M | 0.64% | 810,000 | SH |
| 33 | ZENTALIS PHARMACEUTICALS INC Call | ZNTL | 98943L107 | $2.1M | 0.64% | 426,000 | SH |
| 34 | C4 THERAPEUTICS INC Call | CCCC | 12529R107 | $1.9M | 0.58% | 400,000 | SH |
| 35 | ULTRAGENYX PHARMACEUTICAL IN Call | RARE | 90400D108 | $1.8M | 0.57% | 55,000 | SH |
| 36 | CUE BIOPHARMA INC | CUE | 22978P205 | $1.6M | 0.49% | 50,000 | SH |
| 37 | CALCIMEDICA INC | CALC | 38942Q202 | $1.3M | 0.40% | 1,244,864 | SH |
| 38 | QUINCE THERAPEUTICS INC | IRLA | 22053A305 | $734.4K | 0.23% | 40,375 | SH |
| 39 | NUVECTIS PHARMA INC Call | NVCT | 67080T108 | $711.7K | 0.22% | 38,700 | SH |
| 40 | PASITHEA THERAPEUTICS CORP | KTTA | 70261F202 | $515.4K | 0.16% | 1,000,000 | SH |
| 41 | INMED PHARMACEUTICALS INC | INM | 457637700 | $503.8K | 0.16% | 325,000 | SH |
| 42 | NEUMORA THERAPEUTICS INC. | NMRA | 640979100 | $170.0K | 0.05% | 100,000 | SH |
| 43 | NEXTCURE INC | NXTC | 65343E207 | $103.1K | 0.03% | 64,464 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $322.2M | 43 | 0002050709-26-000027 |
| 2026-03-31 | 2026-05-15 | $272.9M | 37 | 0002050709-26-000017 |
| 2025-12-31 | 2026-02-17 | $236.0M | 33 | 0002050709-26-000010 |
SUITE 1008
OAK BROOK, IL 60523